Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 5/2019

01-05-2019 | Educational Review

Treating the idiopathic nephrotic syndrome: are steroids the answer?

Authors: Georges Deschênes, Claire Dossier, Julien Hogan

Published in: Pediatric Nephrology | Issue 5/2019

Login to get access

Abstract

The use of steroids in idiopathic nephrotic syndrome is the major discovery of the twentieth century in the field of pediatric nephrology. At onset of the twenty-first century, steroids remain the first line of treatment at first flare. All the protocols to treat the first flare are similar by a common sequence including a first phase of daily prednisolone/prednisone at a dose of 60 mg/m2/day for at least 4 weeks followed by an alternate-day regimen for several weeks. It appears that a cumulated dose of 2240 mg/m2 given in 8 weeks at the first flare without tapering sequence is not inferior to increased dose and duration in terms of prevalence of frequent relapsers and the subsequent cumulated dose of steroids at 24 months of follow-up. A higher cumulated dose might only be interesting in patients aged below 4 years although a formal demonstration is still missing. Several retrospective studies are concordant to suggest that intravenous methylprednisolone pulses are useful to reach a full urinary remission in case of oral resistance to 4 weeks of oral prednisone/prednisolone. A majority of patients have multiple relapses after the treatment of the first flare and half meet the definition of steroid dependency. In those patients, long-lasting alternate-day prednisone/prednisolone therapy does not lead to long-lasting remission, opening the question of the best strategy of immunosuppression.
Literature
1.
Riley CM (1950) The effect of adrenocorticotrophic hormone on salt and water excretion in children with the nephrotic syndrome. Am J Dis Child 80:520–521
2.
Barnett HL, Mc NH, Mc CW, Forman C, Rapoport M, Michie A, Barbero G (1950) The effects of ACTH and cortisone on the nephrotic syndrome. Am J Dis Child 80:519–520
3.
4.
Drummond KN, Michael AF, Good RA, Vernier RL (1966) The nephrotic syndrome of childhood: immunologic, clinical, and pathologic correlations. J Clin Invest 45:620–360CrossRefPubMedPubMedCentral
5.
Deschenes G, Vivarelli M, Peruzzi L (2017) Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr 176:647–654CrossRefPubMed
6.
KDIGO (2012) KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2:139–274CrossRef
7.
Spencer RL, Chun LE, Hartsock MJ, Woodruff ER (2017) Glucocorticoid hormones are both a major circadian signal and major stress signal: How this shared signal contributes to a dynamic relationship between the circadian and stress systems. Front Neuroendocrinol S0091-3022(17)30103–30106. https://​doi.​org/​10.​1016/​j.​yfrne
8.
9.
Purton JF, Monk JA, Liddicoat DR, Kyparissoudis K, Sakkal S, Richardson SJ, Godfrey DI, Cole TJ (2004) Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J Immunol 173:3816–3824CrossRefPubMed
10.
Andreau K, Lemaire C, Souvannavong V, Adam A (1998) Induction of apoptosis by dexamethasone in the B cell lineage. Immunopharmacology 40:67–76CrossRefPubMed
11.
12.
Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M, Ramonda R, Iaccarino L, Doria A (2011) The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 10:305–310CrossRefPubMed
13.
Pasini A, Aceto G, Ammenti A, Ardissino G, Azzolina V, Bettinelli A, Cama E, Cantatore S, Crisafi A, Conti G, D’Agostino M, Dozza A, Edefonti A, Fede C, Groppali E, Gualeni C, Lavacchini A, Lepore M, Maringhini S, Mariotti P, Materassi M, Mencarelli F, Messina G, Negri A, Piepoli M, Ravaglia F, Simoni S, Spagnoletta L, Montini G, (2015) Best practice guidelines for idiopathic nephrotic syndrome: recommendations versus reality. Pediatr Nephrol 30:91–101
14.
Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, Kalaivani M, Hari P, Bagga A (2015) Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int 87:217–224CrossRefPubMed
15.
Teeninga N, Kist-van Holthe JE, van Rijswijk N, de Mos NI, Hop WC, Wetzels JF, van der Heijden AJ, Nauta J (2013) Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol 24:149–519CrossRefPubMed
16.
Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, Ishikura K, Hataya H, Honda M, Ito S, Shima Y, Kaito H, Nozu K, Nakamura H, Igarashi T, Ohashi Y, Iijima K (2015) A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 87:225–232CrossRefPubMed
17.
Webb N, Wooley R, Bretell E, Cummins C, Trompeter R, Barsoum E, Ives N, investigators P (2017) Standard vs. extended course prednisolone therapy for the presenting episode of steroid sensitive nephrotic syndrome: the PREDNOS study. Pediatr Nephrol 32:1647–1648CrossRef
18.
Teeninga N, Guan Z, Stevens J, Kist-van Holthe JE, Ackermans MT, van der Heijden AJ, van Schaik RH, van Gelder T, Nauta J (2016) Population pharmacokinetics of prednisolone in relation to clinical outcome in children with nephrotic syndrome. Ther Drug Monit 38:534–545CrossRefPubMed
19.
Ekka BK, Bagga A, Srivastava RN (1997) Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol 11:597–599CrossRefPubMed
20.
21.
Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS (1985) Long-term outcome for children with minimal-change nephrotic syndrome. Lancet 1:368–370CrossRefPubMed
22.
Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Suganuma N, Mayumi M (2003) A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis 41:1155–1562CrossRefPubMed
23.
Hoyer PF, Brodeh J (2006) Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol 17:1151–1157CrossRefPubMed
24.
Schijvens AM, Dorresteijn EM, Roeleveld N, Ter Heine R, van Wijk JAE, Bouts AHM, Keijzer-Veen MG, van de Kar N, van den Heuvel L, Schreuder MF (2017) REducing STEroids in relapsing nephrotic syndrome: the RESTERN study—protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. BMJ Open 7:e018148CrossRefPubMedPubMedCentral
25.
APN (1982) Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med 306:451–454CrossRef
26.
Vivarelli M, Massella L, Ruggiero B, Emma F (2017) Minimal change disease. Clin J Am Soc Nephrol 12:332–345CrossRefPubMed
27.
Broyer M, Kleinknecht C (1978) Traitement des néphroses corticosensibles par la corticothérapie discontinue prolongée. In: Mathieu H (ed) Journée Parisienne de Pédiatrie. Flammarion Médecine Science, Paris, pp 158–710
28.
Srivastava RN, Vasudev AS, Bagga A, Sunderam KR (1992) Long-term, low-dose prednisolone therapy in frequently relapsing nephrotic syndrome. Pediatr Nephrol 6:247–250CrossRefPubMed
29.
Gulati A, Sinha A, Sreenivas V, Math A, Hari P, Bagga A (2011) Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6:63–69CrossRefPubMedPubMedCentral
30.
Abeyagunawardena AS, Trompeter RS (2008) Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Arch Dis Child 93:226–228CrossRefPubMed
31.
Abeyagunawardena AS, Thalgahagoda RS, Dissanayake PV, Abeyagunawardena S, Illangasekera YA, Karunadasa UI, Trompeter RS (2017) Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome. Pediatr Nephrol 32:1377–1382CrossRefPubMed
32.
Broyer M, Terzi F, Lehnert A, Gagnadoux MF, Guest G, Niaudet P (1997) A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome. Pediatr Nephrol 11:418–422CrossRefPubMed
33.
Singhal R, Pandit S, Dhawan N (2015) Deflazacort versus prednisolone: randomized controlled trial in treatment of children with idiopathic nephrotic syndrome. Iran J Pediatr 25:e510CrossRefPubMedPubMedCentral
34.
Gennari C, Imbimbo B, Montagnani M, Bernini M, Nardi P, Avioli LV (1984) Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int 36:245–252CrossRefPubMed
35.
Foster BJ, Shults J, Zemel BS, Leonard MB (2006) Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 21:973–980CrossRefPubMed
36.
Leroy V, Baudouin V, Alberti C, Guest G, Niaudet P, Loirat C, Deschenes G, Czernichow P, Simon D (2009) Growth in boys with idiopathic nephrotic syndrome on long-term cyclosporin and steroid treatment. Pediatr Nephrol 24:2393–2400CrossRefPubMed
37.
Motoyama O, Iitaka K (2007) Final height in children with steroid-sensitive nephrotic syndrome. Pediatr Int 49:623–625CrossRefPubMed
38.
Simmonds J, Grundy N, Trompeter R, Tullus K (2010) Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. Arch Dis Child 95:146–149CrossRefPubMed
39.
Kaye LD, Kalenak JW, Price RL, Cunningham R (1993) Ocular implications of long-term prednisone therapy in children. J Pediatr Ophthalmol Strabismus 30:142–144PubMed
40.
Gulati S, Gulati K (2005) Bone disease in nephrotic syndrome—prevention is better than cure. Pediatr Nephrol 20:111–112CrossRefPubMed
41.
Ksiazek J, Niemirska A, Lipka M, Grenda R (2006) Evaluation of arterial intima-media thickness (IMT) in children with idiopathic nephrotic syndrome—preliminary report. Przegl Lek 63(Suppl 3):205–207PubMed
42.
Zajaczkowska M, Papierkowski A, Szczepanowska A, Zinkiewicz Z, Borzecka H, Zbaranska S (2001) Influence of glucocorticoid steroid therapy on gastric and duodenal mucosa and helicobacter pylori infection in children with nephrotic syndrome. Pol Merkur Lekarski 10:165–167PubMed
43.
Upadhyay A, Mishra OP, Prasad R, Upadhyay SK, Schaefer F (2016) Behavioural abnormalities in children with new-onset nephrotic syndrome receiving corticosteroid therapy: results of a prospective longitudinal study. Pediatr Nephrol 31:233–238CrossRefPubMed
44.
Ulinski T, Carlier-Legris A, Schlecht D, Ranchin B, Cochat P (2005) Triamcinolone acetonide: a new management of noncompliance in nephrotic children. Pediatr Nephrol 20:759–762CrossRefPubMed
45.
Dehoux L, Hogan J, Dossier C, Fila M, Niel O, Maisin A, Macher MA, Kwon T, Baudouin V, Deschênes G (2016) Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome. Pediatr Nephrol 31:2095–2101CrossRefPubMed
46.
Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP, Zurowska A, Maternik M, Massella L, Emma F, Niaudet P, Cornelissen EAM, Schurmans T, Raes A, van de Walle J, van Dyck M, Gulati A, Bagga A, Davin JC (2018) A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Kidney Int 93:510–518CrossRefPubMed
47.
Kuzma-Mroczkowska E, Skrzypczyk P, Panczyk-Tomaszewska M (2016) Levamisole therapy in children with frequently relapsing and steroid-dependent nephrotic syndrome: a single-center experience. Cent Eur J Immunol 41:243–247CrossRefPubMedPubMedCentral
48.
Baudouin V, Alberti C, Lapeyraque AL, Bensman A, Andre JL, Broux F, Cailliez M, Decramer S, Niaudet P, Deschenes G, Jacqz-Aigrain E, Loirat C (2012) Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol 27:389–396CrossRefPubMed
49.
Mahmoud I, Basuni F, Sabry A, El-Husseini A, Hassan N, Ahmad NS, Elbaz M, Moustafa F, Sobh M (2005) Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant 20:735–472CrossRefPubMed
50.
Kengne-Wafo S, Massella L, Diomedi-Camassei F, Gianviti A, Vivarelli M, Greco M, Stringini GR, Emma F (2009) Risk factors for cyclosporin a nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol 4:1409–1416CrossRefPubMed
51.
Azib S, Macher MA, Kwon T, Dechartres A, Alberti C, Loirat C, Deschenes G, Baudouin V (2011) Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 26:927–932CrossRefPubMed
52.
Zagury A, de Oliveira AL, de Moraes CA, de Araujo Montalvao JA, Novaes RH, de Sa VM, Monteiro de Carvalho DB, Matuck T (2011) Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol 26:915–920CrossRefPubMed
53.
Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K (2017) Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 32:2071–2078CrossRefPubMed
54.
Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guerin V, Lapillonne H, Deschenes G, Ulinski T (2012) Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood—follow-up after CD19 recovery. Nephrol Dial Transplant 27:1083–1089CrossRefPubMed
55.
Hari P, Bagga A, Mantan M (2004) Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr 41:993–1000PubMed
56.
Shenoy M, Plant ND, Lewis MA, Bradbury MG, Lennon R, Webb NJ (2010) Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr Nephrol 25:899–903CrossRefPubMed
57.
Zhang H, Wang Z, Dong LQ, Guo YN (2016) Children with steroid-resistant nephrotic syndrome: long-term outcomes of sequential steroid therapy. Biomed Environ Sci 29:650–655PubMed
58.
Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J (2007) Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 22:2183–2193CrossRefPubMed
Metadata
Title
Treating the idiopathic nephrotic syndrome: are steroids the answer?
Authors
Georges Deschênes
Claire Dossier
Julien Hogan
Publication date
01-05-2019
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 5/2019
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-018-3963-x

Other articles of this Issue 5/2019

Pediatric Nephrology 5/2019 Go to the issue

Clinical Quiz

An unusual cause of nephrotic syndrome: Answers

Clinical Quiz

Dangerous hyperkalemia in a newborn: Answers

Original Article

The aminoglycoside geneticin permits translational readthrough of the CTNS W138X nonsense mutation in fibroblasts from patients with nephropathic cystinosis

Editorial Commentary

IgA nephropathy: is a new approach beyond proteinuria necessary?

Abstracts

The XLIII Spanish Congress of Pediatric Nephrology

Review

Zebrafish as a model for kidney function and disease